Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation -- Company Announces Four-Day Subsequent Offer Period for Remaining Shareholders -- Genzyme Becomes a Subsidiary of...
Standard & Poor's Announces Change to U.S. Index PR Newswire NEW YORK, March 29, 2011 NEW YORK, March 29, 2011 /PRNewswire/ -- BlackRock Inc. (NYSE: BLK) will replace Genzyme Corp. (NASD: GENZ...
Genzyme Corporation (NASDAQ: GENZ) announced today that its Board of Directors unanimously recommends that Genzyme shareholders accept the sanofi-aventis revised tender offer...
Genzyme Corporation (Nasdaq: GENZ) today announced that it has completed the sale of its pharmaceutical intermediates business to International Chemical Investors Group...
Genzyme Corporation (NASDAQ: GENZ) today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards (PAL...
Genzyme Corporation (NASDAQ: GENZ) today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for...
Genzyme Corp. (NASDAQ: GENZ) today reported fourth-quarter 2010 results that reflect increasing supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase...
Video Available: Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right Combination will enhance sanofi-aventis' sustainable growth strategy by expanding its...
Sanofi-aventis to Acquire Genzyme for $74.00 in Cash Per Share Plus Contingent Value Right -- Combination will enhance sanofi-aventis' sustainable growth strategy by expanding its footprint in...
Zacks Analyst Blog Highlights: Laboratory Corporation of America Holdings, Genzyme, Quest Diagnostics, Penn Virginia Resource Partners L.P. and Cloud Peak Energy PR Newswire CHICAGO, Feb. 11...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales